Table 2.
Follow up | ||||||
Reference | n | (months)† | Death (%) | MI (%) | TVR (%) | MACE (%) |
[42] | 123 | 42 | 13 | 22 | 21 | 49 |
[4] | 301 | 24 | 4.6 | 4.3* | 20.4 | 29.3 |
[43] | 65 | 39 | 10.8 | 6.2 | 30.8 | 44.0 |
[44] | 175 | 54 | 13.7 | 12.6 | 39.4 | 49.7 |
[33] | 143 | 36 | 9.1 | 5.6* | 20.4 | 25.4 |
[45] | 229 | 48 | 2.7 | 2.2* | 12.0 | 16.9 |
[46] | 259 | 60 | 5.9 | 7.8 | 25.0 | 34.5 |
[47] | 1000 | 29 | 8.2 | 12.8 | 30.3 | 45.0 |
*Nonfatal infarctions. †Mean or median follow-up period. MACE, major adverse clinical event; MI, myocardial infarction.